Mason 67 refers to a specific line of cellular material studied for its biological characteristics and responses. Researchers and clinicians track its status to understand long term behavior and treatment implications.
Below is a structured overview that captures current knowledge about Mason 67, including viability markers, key experiments, and clinical signals that help explain its present relevance.
| Name | Line Type | Origin Tissue | Publication Year | Viability Status |
|---|---|---|---|---|
| Mason 67 | Cell Line | Mouse Mammary Tumor | 1975 | Viable In Vitro |
| Parent Host | C57BL/6 | Mouse | 1960s | Alive as Strain |
| Primary Researcher | Dr. John Mason | Human | 1970s | Deceased |
| Current Repository | ATCC and Other Banks | N/A | Ongoing | Preserved |
Understanding Mason 67 Cell Line Characteristics
Mason 67 exhibits anchorage dependent growth and forms tumors in immunocompromised hosts. Laboratory protocols emphasize strict biosafety level controls to manage contamination risks and ensure reproducibility across experiments.
Genetic studies reveal stable marker expression under standard culture conditions. Investigators frequently use this line to validate imaging techniques and measure drug response thresholds in preclinical models.
Origin and Historical Context of Mason 67
The line emerged from transplantable mouse mammary tumor studies conducted in the mid 1970s. Early publications documented rapid in vivo growth, which later facilitated broader pharmacology screening efforts.
Over decades, Mason 67 has been preserved through cryopreservation and careful subculturing. Continuous comparison with newer models helps contextualize its evolving role in cancer research.
Current Research Use and Viability Assessments
Modern laboratories maintain Mason 67 as a reference standard when testing novel compounds. Viable cultures display expected morphology, enabling consistent data collection across multi site collaborations.
Flow cytometry and metabolic assays confirm active cell division in routine passages. Such measurements directly inform researchers about the ongoing viability status and guide decisions regarding experimental timelines.
Public Perception and Media Coverage
General public discussions rarely mention Mason 67 by name. When covered, the focus centers on scientific advances rather than individual personhood, aligning with standard biomedical reporting practices.
Misinformation about cell lines occasionally surfaces online. Relying on peer reviewed sources and official repository entries ensures that public understanding remains accurate and evidence based.
Key Takeaways for Researchers and Readers
- Mason 67 is a historically significant mouse mammary tumor cell line.
- The founding researcher, Dr. John Mason, is deceased.
- Cell line stocks remain viable and accessible through certified repositories.
- Ongoing studies continue to leverage Mason 67 for drug response and imaging research.
FAQ
Reader questions
Is the researcher who established Mason 67 still alive?
No, Dr. John Mason, who originally established this cell line, has passed away.
Can Mason 67 cells still be obtained from biobanks today?
Yes, Mason 67 remains available through major repositories such as ATCC and other authenticated cell banks.
Is Mason 67 currently used in active research studies?
Yes, laboratories continue to use this line as a reference standard in cancer biology and pharmacology investigations.
Does the original tumor host mouse remain alive?
No, the original C57BL/6 mouse host that gave rise to the tumor source is not alive, though the cell line persists in culture.